Streams live, Wednesday at 1 p.m. ET / 10 a.m. PT.
For 23 years, doctors were legally required to terrify women about the one treatment that could have changed their lives.
This week, the FDA finally admitted they got it catastrophically wrong. The black box warning on hormone replacement therapy? Gone.
Fifty million women were denied relief from menopause symptoms—hot flashes, brain fog, bone loss, sleep disruption—because of a study that’s been debunked for years.
Even the FDA’s own commissioner called it “one of the greatest screw-ups in modern medicine.”
And while they’re patting themselves on the back, Procter & Gamble is selling a $40 menopause test kit that lawsuits say is built on fraudulent science. Bad studies. Corporate profit. Women’s suffering.
It’s the same story on repeat. They finally told the truth about HRT after 23 years. How many more decades before they admit what they’re lying about now?
Each episode, your hosts Karen and Mia cut through the noise with sharp commentary, headline debunking, expert interviews, and practical metabolic advice you won’t hear anywhere else. From retracted “miracle” studies to Reddit-fueled health myths, we’re setting the record straight.
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
